Trustner AcademyTrustner AcademyCourses
Reading 1CFA L2 CorpFull chapter

Corporate restructuring — M&A and divestitures

In this chapter: Synergies (cost, revenue, financial) · Deal structuring (cash, stock, mixed) · Valuation methods · Anti-takeover defences · Tax considerations

~3 min readLayer 4 · Professional CertificationsFree

M&A creates value when combined firm worth > sum of parts. CFA L2 tests recognising types of synergy, valuing deals (DCF, comparables, precedents), and analysing post-deal accretion/dilution.

Foundation

Synergy types: - **Cost synergies**: redundant facility/staff elimination (most reliable, quickest). - **Revenue synergies**: cross-selling, distribution expansion (slower, often overestimated). - **Financial synergies**: tax loss carry-forwards, debt capacity (debatable; depends on tax/reg). - **Operating synergies**: economies of scale + scope. Deal valuation approaches: 1. **DCF**: project synergised cash flows, discount at WACC. 2. **Comparable company**: trading multiples (EV/EBITDA, P/E) of similar firms. 3. **Comparable transaction**: precedent multiples in similar deals (typically include control premium). 4. **Premium analysis**: bid premium vs target market price (typically 20-40%). Deal structures: - All cash: certainty for target; uses acquirer cash/debt. - All stock: target shares subject to combined-firm risk. - Mixed: most common.

Deep Dive

Accretion/dilution analysis — does deal increase acquirer EPS? - All-cash deal: borrow to fund. Interest expense + new shares (if issued). EPS impact = (target NI + synergies − after-tax interest) / acquirer shares. Accretive if target P/E > 1/(after-tax cost of debt). - All-stock deal: dilutive if acquirer P/E < target P/E (after deal). Anti-takeover defences: - **Pre-bid**: poison pill, staggered board, super-majority voting, golden parachute. - **Post-bid**: white knight, Pac-Man, crown jewel, leveraged recap. M&A regulatory: - US: HSR Act for antitrust review. - India: CCI (Competition Commission of India) approval if thresholds breached. - SEBI takeover code (SAST) for listed targets >25% stake → mandatory open offer.

Advanced

Practitioner insight: most M&A destroys value (research shows acquirer shares often underperform). Reasons: - Overpayment (winner's curse). - Synergies overestimated. - Cultural integration failures. Valuation tip: never anchor on bid premium alone. Build standalone DCF for target + synergy sensitivity. The synergies you assume must be both ID-able and at risk. Divestiture analysis: when does selling a unit create value? When PV of independent unit > value as part of conglomerate (conglomerate discount).

Regulatory references
  • SEBI SAST Regulations 2011
  • Companies Act 2013 — Mergers and Amalgamations
  • CCI Combination Regulations
  • CFA Institute Corp Issuers curriculum
Common mistakes & pitfalls
  • Treating control premium as deserved rather than negotiated outcome.
  • Underestimating integration costs (typically 1-3 years before synergies materialise).
  • Ignoring revenue dis-synergies (lost customers due to merger).

Frequently asked

Why does most M&A destroy value?
Overpayment (auction dynamic), overestimated synergies, integration friction, cultural misalignment.
When is all-stock better than all-cash?
When acquirer stock seen as overvalued (paying with "cheap currency"), or target wants tax deferral, or acquirer wants to share risk.

Practice questions

Click each question to reveal the answer and explanation.

Q 1
Cost synergies typically come from:
  1. (a)Tax loss carry-forwards
  2. (b)Redundant facility/staff elimination
  3. (c)New product launches
  4. (d)Stock buybacks
Correct: (b) Redundant facility/staff elimination
Cost synergies = removing duplicates. Reliable and quickest to capture.
Q 2
In all-stock deal, accretion is more likely when:
  1. (a)Acquirer P/E < target P/E
  2. (b)Acquirer P/E > target P/E
  3. (c)P/Es are equal
  4. (d)No relation
Correct: (b) Acquirer P/E > target P/E
When acquirer P/E > target P/E, paying with high-multiple stock is "cheap" → accretion.
Q 3
Poison pill is:
  1. (a)Post-bid defence
  2. (b)Pre-bid defence
  3. (c)Tax strategy
  4. (d)Antitrust filing
Correct: (b) Pre-bid defence
Poison pill = pre-bid defence. Allows existing shareholders to buy more shares cheaply if hostile bidder crosses threshold.
Q 4
SEBI SAST mandatory open offer triggered at:
  1. (a)10% stake
  2. (b)15% stake
  3. (c)25% stake
  4. (d)51% stake
Correct: (c) 25% stake
SAST: acquiring 25%+ in listed company triggers mandatory open offer for additional 26%.
Q 5
Comparable transaction multiples typically include:
  1. (a)No premium
  2. (b)Control premium
  3. (c)Discount
  4. (d)Same as trading multiples
Correct: (b) Control premium
Precedent transactions include control premium (already paid). Trading multiples don't.
Educational purposes only. The numbers, returns, and examples used in this lesson are illustrative. Past performance does not guarantee future results. Mutual fund and securities investments are subject to market risks. This lesson is not investment advice; for advice tailored to your circumstances, consult a SEBI-registered Investment Adviser. Read our full disclaimer.